With a diverse pipeline featuring oral drug candidates like VK2809 for NASH and NAFLD, VK5211 for hip fracture recovery, and VK2735 for weight loss, it’s advancing treatments across a range of ...

Viking Therapeutics is looking to carve out a niche thanks to VK2735, a potential anti-obesity therapy that aced phase 2 studies last year. True, this mid-cap biotech still looks risky.

Conference call scheduled for 4:30 p.m. ET todayInitiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25Phase 2 VENTURE-Oral Dosing Trial Evaluating ...

With a diverse pipeline featuring oral drug candidates like VK2809 for NASH and NAFLD, VK5211 for hip fracture recovery, and VK2735 for weight loss, it’s advancing treatments across a range of ...

Shares surged as high as $99.41 in the following days. VK2735 is such a profound contender that an Oppenheimer research analyst upgraded the price target to $138 per share on March 26, 2024.

The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of VK2735 in the second quarter. It's also advanced an oral version ...

However, there are many contenders in the works. One of the most promising GLP-1 contenders is VK2735, a dual GLP-1/GIP receptor agonist similar to tirzepatide, owned by Viking Therapeutics Inc ...